A Phase III Clinical Trial Evaluating DCVax«-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme.

Objective

The purpose of this study is to see if an investigational agent known as DCVax-Brain can slow the growth and recurrence of your brain tumor and whether it can extend overall survival. Other goals are to test the safety and activity of DCVax-Brain and to determine whether it causes an immune response against your cancer cells as compared to standard treatment. DCVax-Brain is an investigational agent made from your own blood cells which have been exposed to your own tumor tissue. The study agent OR placebo will be given by injection.

IRB Protocol Number

11-1777

Principal Investigator(s)

KEVIN LILLEHEI

Cancer Trials

• Brain and Nervous System Tumors

Sponsor(s)

Northwest Biotherapeutics

Contact

MONICA ROBISCHON at 720-848-0661
or MONICA.ROBISCHON@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : Following a screening period to determine your eligibility, the active treatment phase lasts up to 36 months and begins after recovery from surgery, radiation therapy and chemotherapy. The follow-up phase starts after the 36 months is completed or after you leave the study for any reason. During the follow-up phase you and/or a designated contact will be contacted every third month to ask how you are doing for the rest of your life. // Eligibility criteria include but are not limited to: persons 18 years and older with Glioblastoma Multiforme.